Intervention not reported
Sputum conversion at 6 months · patients with managing pulmonary tuberculosis
The intervention showed no clear difference in sputum conversion at 6 months (moderate certainty).
1 finding from 1 review
Intervention not reported
Clinical Improvement at 1 month · patients with managing pulmonary tuberculosis
It is very uncertain whether the intervention changes clinical Improvement at 1 month (very low certainty).
1 finding from 1 review
Adverse events at study endpoint · patients with chronic obstructive pulmonary disease
Mometasone/formoterol (MF/F) showed no clear difference in adverse event—any—400/103 Duration of six months compared with placebo (low certainty).
2 findings from 1 review
OR 0.98 [0.75, 1.3]
890 participants
Low
OR 0.82 [0.62, 1.09]
894 participants
Low
Adverse events—serious—400/103 Duration of six months · patients with chronic obstructive pulmonary disease
Mometasone/formoterol (MF/F) showed no clear difference in adverse events—serious—400/103 Duration of six months compared with placebo (low certainty).
1 finding from 1 review
OR 1.09 [0.66, 1.79]
890 participants
Low
Adverse events—serious—200/103 Duration of six months · patients with chronic obstructive pulmonary disease
Mometasone/formoterol (MF/F) showed no clear difference in adverse events—serious—200/103 Duration of six months compared with placebo (low certainty).
1 finding from 1 review
OR 0.71 [0.41, 1.23]
894 participants
Low
Intervention not reported
Survival · patients with unresectable periampullary carcinoma
It is very uncertain whether the intervention changes survival (very low certainty).
1 finding from 1 review
Intervention not reported
Gastric outlet obstruction Clinical symptoms of vomiting with confirmation of the gastric outlet obstruction by radiological or endoscopic investigations · patients with unresectable periampullary carcinoma
It is very uncertain whether the intervention changes gastric outlet obstruction Clinical symptoms of vomiting with… (very low certainty).
1 finding from 1 review
Intervention not reported
Operating time · patients with unresectable periampullary carcinoma
1 finding from 1 review
Outcomes · patients with chronic obstructive pulmonary disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life St George's Respiratory Questionnaire (SGRQ) score · patients with chronic obstructive pulmonary disease
Long‐acting beta2‐agonists showed no clear difference in quality of life1 St George's Respiratory Questionnaire (SGRQ); lower… compared with placebo (moderate certainty).
1 finding from 1 review
Severe exacerbations requiring hospitalisation over the study period · patients with chronic obstructive pulmonary disease
Long‐acting beta2‐agonists probably leads to lower severe exacerbations (hospitalisations) compared with placebo (moderate certainty).
1 finding from 1 review
Moderate exacerbations (course of antibiotics or oral steroids) · patients with chronic obstructive pulmonary disease
Long‐acting beta2‐agonists probably leads to lower moderate exacerbations (course of antibiotics or oral steroids) compared with placebo (moderate certainty).
1 finding from 1 review
Moderate‐to‐severe exacerbations (rate) · patients with chronic obstructive pulmonary disease
Long‐acting beta2‐agonists showed no clear difference in severe/moderate exacerbations (hospitalisation or course of… compared with placebo (moderate certainty).
1 finding from 1 review
Mortality (all‐cause) · patients with chronic obstructive pulmonary disease
Long‐acting beta2‐agonists showed no clear difference in mortality (all‐cause) compared with placebo (moderate certainty).
1 finding from 1 review
Participants with one or more serious adverse event (non‐fatal) · patients with chronic obstructive pulmonary disease
Long‐acting beta2‐agonists showed no clear difference in participants with one or more serious adverse event (non‐fatal) compared with placebo (moderate certainty).
1 finding from 1 review
FEV1 · patients with chronic obstructive pulmonary disease
Long‐acting beta2‐agonists showed no clear difference in predose FEV1 (mL) compared with placebo (low certainty).
1 finding from 1 review
Intervention not reported
FEV1 % predicted · stable chronic obstructive pulmonary disease
1 finding from 1 review
Intervention not reported
MIP ‐ undernourished cm H2O · stable chronic obstructive pulmonary disease
1 finding from 1 review
Intervention not reported
HRQoL ‐ SGRQ ‐ subgrouped by domain ‐ total · stable chronic obstructive pulmonary disease
1 finding from 1 review
Intervention not reported
HRQoL ‐ SGRQ subgrouped by domain ‐ activity · stable chronic obstructive pulmonary disease
1 finding from 1 review